Incannex Healthcare Achieves interim milestone in psilocybin trial
Incannex Healthcare (IHL) achieves an interim milestone in its clinical trial to treat generalised anxiety disorder
...
Incannex Healthcare Completes phase 2 clinical trial of IHL-42X
Incannex Healthcare (IHL) completes the phase two trial of its cannabinoid combination drug IHL-42X
The...
Incannex Healthcare has received ethics approval for a phase 2b clinical trial investigating its obstructive sleep apnoea (OSA) treatment
OSA occurs when the...
Incannex Healthcare: Expects record sales in June quarter
Incannex Healthcare (IHL), formerly known as Impression Healthcare, expects to report $671,000 in cash sales receipts...
